人参联合常规疗法治疗稳定型心绞痛临床随机对照试验的Meta分析

A Meta-analysis of Ginseng combined with conventional therapy for stable angina pectoris

目的:系统评价人参联合常规疗法治疗稳定型心绞痛(SAP)的临床疗效。方法:计算机检索外文数据库:Cochrane Library、Pubmed、Embase、Web of Science,以及中文数据库:中国学术期刊全文数据库(CNKI)、万方数据库(Wanfang)、维普数据库(VIP)、中国生物医学文献数据库(CBM),纳入有关人参联合常规疗法治疗SAP临床随机对照试验(RCT),评价文献质量后,使用RevMan 5.3和Stata 15.0软件进行Meta分析。结果:最终符合纳入标准文献共13篇,总例数1176例,包括试验组606例,对照组570例。Meta分析显示,人参联合常规疗法对SAP临床有效率[RR=1.29,95%CI(1.21,1.36),P<0.00001]、心电图有效率[RR=1.35,95%CI(1.22,1.50),P<0.00001];心绞痛发作次数[MD=-1.77,95%CI(-2.64,-0.91),P<0.00001]、心绞痛持续时间[MD=-2.16,95%CI(-2.54,-1.78),P<0.00001]、硝酸甘油用量[MD=-1.52,95%CI(-1.81,-1.23),P<0.00001]均有一定疗效,且优于单独使用常规疗法。结论:人参联合常规疗法较治疗SAP能明显提高临床有效率和心电图有效率、减少心绞痛发作次数、缩短心绞痛持续时间、减少硝酸甘油用量。人参相关中成药的研发具有良好前景。但纳入文献质量为中低水平,仍需更高质量的RCT研究加以证实。

Objective To evaluate the efficacy of Ginseng combined with conventional therapy for stable angina pectoris(SAP).Methods From the Cochrane Library,Pubmed,Embase,Web of Science,CNKI(China National Knowledge Infrastructure),Wanfang Datebase,VIP(Chinese Scientific Journals Database),CBM(Chinese Biomedicine Database),we reviewed the clinical randomized controlled trial(RCT),after screening and assessing the risk of bias,used RevMan 5.3 and Stata 15.0 software to conduct the meta-analysis.Results Twelve studies were included with 1176 cases,involving 606 cases in the experimental group and 570 in the control group.The results of meta-analysis showed that Ginseng combined with conventional therapy significantly has obvious effect on clinical effective rate(RR=1.29,95%CI1.21,1.36,P<0.00001),ECG effective rate(RR=1.35,95%CI1.22,1.50,P<0.00001),number of angina attacks(MD=-1.77,95%CI-2.64,-0.91,P<0.00001),duration of angina pectoris(MD=-2.16,95%CI-2.54,-1.78,P<0.00001),nitroglycerin dosage(MD=-1.52,95%CI-1.81,-1.23,P<0.00001),and it is better than using conventional therapy alone.Conclusion Ginseng combined with conventional therapy for SAP can significantly improve clinical effective rate and ECG effective rate,reduce the number of angina attacks,shorten the duration of angina pectoris,and reduce nitroglycerin dosage.The development of ginseng-related proprietary Chinese medicines has good prospects.But due to the quality of studies is medium and low,it still needs to be confirmed by conducting high-quality RCTs.